Abstract
The value of biological drugs indicated for autoimmune diseases, which affect
up to 5% of the total world population, was roughly $11 billion in 2005.
Remicade, Enbrel, Humira and Avonex currently lead the autoimmune field. These
drugs are transforming the treatment of autoimmune diseases. In addition,
novel therapies for psoriasis, asthma, and lupus will in the near future add
tremendous revenue to an already rapidly growing field.
Medical, pharmaceutical and biotechnological advances are increasingly
supporting the use of biological drugs in the treatment of autoimmune and
inflammatory diseases. Indeed, biologics are having a major impact on the
treatment of those diseases for which there has been significant unmet need
for decades. As the new drugs are capable of targeting disease-causing
proteins in a more specific fashion, while also carrying lower risks of
adverse side effects, they have considerable advantages over traditional
treatments.
Given the above advantages, coupled with more commercial interest, better
understanding of disease causes and higher levels of patient familiarity with
the new medicines, biologics will continue to undermine the market share of
traditional drugs.
This report assesses the current and future position of biologics in the
fields of multiple sclerosis, rheumatoid arthritis, inflammatory bowel
disease, systemic lupus erythematosus, psoriasis and asthma.
Key Features of This Report:
- Thorough financial breakdown of the leading products and companies making
an impact in autoimmune
- disease therapy
- Market analysis and differentiation of biotech vs. synthetic drugs in
combatting autoimmune diseases
- Financial forecasts for key autoimmune disease therapies as well as
overall disease category value
- through 2010
- Integrative discussion of clinical data and key trials for already
marketed as well as emerging biologics
- Identification and discussion of trends and issues that will have a
significant impact on the future of
- biotech drug sales in the autoimmune market
- Appraisal of development status for key biotech drugs being developed for
various autoimmune diseases
- and discussion of research trends
Who Should Buy This Report:
- Companies interested in understanding the wider opportunities and
challenges in the autoimmune and
- inflammatory disease markets
- Pharma/biotech companies wishing to identify opportunities and threats to
products in these markets in
- order to examine a variety of profit maximization strategies
- Companies interested in understanding the state of R&D in relation to
multiple sclerosis, rheumatoid
- arthritis, inflammatory bowel disease, systemic lupus erythematosus,
psoriasis and asthma
| 
View Cart
